Floatz logo

Fosaprepitant Dimeglumine

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Fujian Shengdi Pharmaceutical Co., Ltd.Phase 3Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy cohort.

Asset / SponsorPhaseRating
HR20013
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3BB

Same molecule, other indications

Fosaprepitant Dimeglumine is also rated in:

cancer of unknown primary siteDormant
C
Indicative ·
33 / 100
View asset →
NauseaDormant
D
Indicative ·
30 / 100
View asset →
VomitingDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →